about
Identification of multiple genetic susceptibility loci in Takayasu arteritisCirculating angiopoietin-2 as a biomarker in ANCA-associated vasculitisCardiovascular magnetic resonance in rheumatology: Current status and recommendations for use.Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.BK virus replication in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Small-vessel and medium-vessel vasculitis.Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association StudyOlder patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study.Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysisValue of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.Cardiac Involvement in Granulomatosis with PolyangiitisDisease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitisCurrent status of outcome measure development in vasculitis.Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritisThe OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.Pregnancy and vasculitis.Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.Biologic agents in systemic vasculitis.Renal transplantation in the ANCA-associated vasculitides.The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis.Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis.Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritisMacular lymphocytic arteritis: Clinical-pathologic correlation of a rare vasculitis.Vasculitis in the intensive care unit.Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab.Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated VasculitisANCA-Associated Vasculitis Pathogenesis: A Commentary.Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis.A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.
P50
Q24632711-4BDF7D79-7D5A-4BCE-BEF9-1117ED0B4591Q28732725-95AA93B6-A038-4C1B-8CD9-F866558886FAQ30250316-6B097AF1-2121-4A7E-8B0F-2B24930C9367Q30993164-1D6FA3ED-5D66-4962-AF30-9AC9756D1B93Q33862188-51C72623-042F-4B98-BF95-B45E9D64F743Q34081869-7BEA9069-C992-4484-AAED-1A0E804470FAQ34111969-E68305C5-DE00-4182-B308-D6F50063F82AQ34500502-227EBFCD-2844-4C6D-A60D-73637B29BF2BQ34720170-8325FF11-E28F-484B-BE91-E42F91ADD6FEQ35124613-806A87A5-14FE-4088-AAB3-E53ACEC382A1Q35220126-5C29CC9F-3FD7-450E-AB55-ED9CF90C961DQ35266391-4F743268-3A7F-4A03-886A-F6657530F4A4Q35554373-21884B95-5457-4CCD-9248-D4B89D0A232BQ35673484-9FD13AB4-797B-4B29-B2A5-544B082F43BDQ35754787-E4FDA5E4-2970-49D4-89B9-5E6A107F608BQ35851773-D1EFE164-715E-4029-978C-4C2D8FA022E0Q35861654-2C8C6180-ED94-4867-A030-C9E8F3BEC8EBQ35861674-357B1177-2F19-4FF8-ACCB-016BAFC0095CQ35861689-6B6DF3E4-FBC6-442C-8D16-77D4D5081406Q35865798-3164E791-00E5-431E-9E84-BCDAA3148284Q35890027-13EE639D-5554-4B07-8A7A-C6E197C89E41Q36183352-34A57C48-33E1-4D70-B869-3A588C97C279Q36820858-FB3BF44B-2BF0-476B-9224-E991ED620958Q36820997-BB691BD7-8E7D-4BAA-A8D5-1EA6E822E92FQ36843077-A5FDFF72-93A5-4A2B-B057-79BF40E13896Q36934322-07E6F46D-FDE5-403C-9A3F-2B1B11A86AAEQ36956903-C13C9283-94FB-4591-BB48-6ED5A08FB6FDQ36963349-72855556-3C1B-4FAF-934C-D8DDEABF6E9EQ37006816-C8A1B1BE-B1B0-4C3A-B7B6-72FDF3F9A772Q37060366-329D98C8-1AA3-4E5A-AEA2-E60F0A25BC3DQ37060375-75105079-A95C-4478-95E9-FD7E431CE41AQ37698639-019E3320-2335-44A6-B5D2-F9ED8BFD8065Q38090846-44668671-765F-4F25-98C8-6A41FBBF9099Q38155087-A135919E-0409-4BD5-9ED5-410878E4625CQ38840696-1194E736-E461-4777-98C4-944F6F4DF857Q39059159-E939CEBF-EAE3-406A-A607-E194CC53F888Q39210329-6C81607A-768B-48A3-B826-C7274C171C57Q39993490-3A505314-FE6A-4991-B4F7-35A43A063A82Q40353901-2775C6D8-8015-44CB-A5E3-12D17A001A54Q40353912-FE3BE48C-F0A4-497E-99D5-C85DF4833CF4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Philip Seo
@ast
Philip Seo
@en
Philip Seo
@es
Philip Seo
@sl
type
label
Philip Seo
@ast
Philip Seo
@en
Philip Seo
@es
Philip Seo
@sl
prefLabel
Philip Seo
@ast
Philip Seo
@en
Philip Seo
@es
Philip Seo
@sl
P106
P21
P31
P496
0000-0003-3435-6737